cv dr iqbal 21.12.2015

50
Dr Zafar Iqbal M.Phil., Ph.D., Postdoctorate Assistant Professor (Medical Genetics /Hematology & Oncology) King Saud Bin Abdulaziz University for Health Sciences King Abdulaziz Medical City, National Guard Health Affairs Riyadh 11426, Saudi Arabia. Phone: +966-53-86-355-86 / -11-42-95320 E-mail: [email protected] / [email protected] Academic Qualifications : 1) Fellowship (Medical Genomics / Clinical Hematology) 2007-2008 Shanghai Institute of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine (SJTU), China (Post-doctoral fellowship in Functional Medical Genomics / Clinical Hematology) 2) Ph.D. * (Molecular Genetics / Hematology & Oncology) 2001-2007 SJTU China & University of the Punjab, Lahore, Pakistan. Page 1 of 50

Upload: dr-zafar-iqbal

Post on 14-Feb-2017

322 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: CV Dr Iqbal 21.12.2015

Dr Zafar Iqbal

M.Phil., Ph.D., Postdoctorate

Assistant Professor (Medical Genetics /Hematology & Oncology)

King Saud Bin Abdulaziz University for Health Sciences

King Abdulaziz Medical City, National Guard Health Affairs

Riyadh 11426, Saudi Arabia.

Phone: +966-53-86-355-86 / -11-42-95320

E-mail: [email protected] / [email protected]

Academic Qualifications:

1) Fellowship (Medical Genomics / Clinical Hematology) 2007-2008

Shanghai Institute of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine (SJTU), China

(Post-doctoral fellowship in Functional Medical Genomics / Clinical Hematology)

2) Ph.D. * (Molecular Genetics / Hematology & Oncology) 2001-2007

SJTU China & University of the Punjab, Lahore, Pakistan.

3) M.Phil. (MS) (Molecular Biology / Biomedical sciences) 1999-2001          

Centre of Excellence in Molecular Biology, University of the Punjab, Lahore. 

 

*PhD work was carried out at SJTU School of Medicine Shanghai China, University of Tokyo Hospital Japan and National Institute for Biotechnology & Genetic Engineering (NIBGE), Faisalabad, Pakistan, and degree was awarded by University of the Punjab Lahore Pakistan.

Page 1 of 31

Page 2: CV Dr Iqbal 21.12.2015

List of Publications

Full-text Articles (37):

1. Iqbal Z, Mahmood R, Aleem A. Status of BCR-ABL monitoring in developing

countries and need for careful application for automated Xpert BCR-ABL Monitor™

(Cepheid) system in CML patients: Saudi Arabia as an example. Blood (Online),

12/2015; 126(3):5170 E-Letter. 10.45 Impact Factor.

http://www.bloodjournal.org/content/126/23/5170.e-letters.

2. Rasool M, Iqbal Z, Israr S, Saleem S, Gillani Z, Qazi MH, et al. . BAD, a

Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-

Treated HeLa Cells. PLOS one 2015 December (accepted for publication).

3.23 Impact Factor.

3. Iqbal Z, Khalid K, Akhtar T, Sabir N, Aleem M, Rasool M, et al. High frequency and

poor prognosis of late childhood BCR-ABL positive and MLL-AF4 positive ALL

define the need for advanced molecular diagnostics and improved therapeutic

strategies in pediatric B-ALL in Pakistan. Mol Diagn Ther. 2015 Oct;19(5):277-87.

2.891 Impact Factor

4. Aljamaan K, Aljumah TK, Aloraibi S, Absar M, Iqbal Z. Low Frequency of ETV6-RUNX1 (t

12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with

Clinical Parameters and Early Remission. Asian Pac J Cancer Prev. 2015; 16(17):7523-7.

5. Tahira B, Asif M, Khan S, Hussain A, Shahwani MN, Malik A, Inayatullah S, Iqbal

Z, Rasool M. Detection of BCR/ABL Fusion Gene by Hematological and

Cytogenetical Analysis in Chronic Myeloid Leukemia Patients in Quetta, Pakistan.

Asian Pac J Cancer Prev. 2015; 16(9):3793-7. 2.51 Impact Factor

6. Shahid M, Sabar MF, Bano I, Rahman Z, Iqbal Z, Fatim Ali SS, Ghani MU, Iqbal M,

Husnain T. Sequence variants on 17q21 are associated with the susceptibility

of asthma in the population of Lahore, Pakistan. J Asthma. 2015 Jul 23:1-8.

Page 2 of 31

Page 3: CV Dr Iqbal 21.12.2015

7. Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M, Sani S, Qazi MH, Kamal

MA, Iqbal Z, Hussain A. Assessment of circulating biochemical markers and

antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid

leukemia (AML) patients. Saudi J Biol Sci. 2015 Jan; 22(1):106-11.

8. Iqbal Z. Molecular genetic studies on 167 pediatric ALL patients from different areas

of Pakistan confirm a low frequency of the favorable prognosis fusion oncogene TEL-

AML1 (t 12; 21) in underdeveloped countries of the region. Asian Pac J Cancer Prev.

2014; 15(8):3541-6.

9. Tayyab M, Khan M, Akhtar T, Iqbal Z, Noor Z, Noor N. Distinct Gene Mutations,

their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid

Leukemia (AML). J Cancer Sci Ther 2014, 6:337-349. doi: 10.4172/1948-

5956.1000292. http://omicsonline.org/open-access/distinct-gene-mutations-their-

prognostic-relevance-and-molecularly-targeted-therapies-in-acute-myeloid-

leukemia-aml-1948-5956.1000292.pdf

10. Iqbal Z, Akhtar T, Akram AM, Khalid M, Shah IH, Aleem A, et al. Detection

of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a

Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing

a Newly Developed Cost Effective BCR-ABL Sequencing Protocol. Blood 2014: 124

(21): 1810. http://www.bloodjournal.org/content/124/21/1810.

11. Iqbal Z. A comprehensive analysis of breakpoint cluster region-abelson fusion

oncogene splice variants in chronic myeloid leukemia and their correlation with

disease biology. Indian J Hum Genet. 2014 Jan; 20(1):64-8.

12. Akram A, Akhtar T and Iqbal Z. Survival assessment and Optimization of

BCR/ABL-KD amplification protocol for detection of Imatinib resistant mutations in

Page 3 of 31

Page 4: CV Dr Iqbal 21.12.2015

Ph+ Chronic Myeloid Leukemia patients from Pakistan

Gene therapy & molecular biology 02/2014; 16:10. 0.72 Impact Factor

http://www.gtmb.org/volumes/Vol16/2.Akram_et_al_10-29.pdf

13. Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A.

Immunological evaluation of β-thalassemia major patients receiving oral iron chelator

deferasirox. J Coll Physicians Surg Pak. 2014 Jul;24(7):467-71.

14. Rasool M, Rashid S, Arooj M… Iqbal Z, Gan SH, Kamal MA, Sheikh IA. New

possibilities in hepatocellular carcinoma treatment. Anticancer Res. 2014 Apr;

34(4):1563-71.

15. Rasool M, Malik A, Qazi A, Sheikh I, Manan A, Shaheen S, Iqbal Z et al.

Current View From Alzheimer Disease To Type 2 Diabetes Mellitus. CNS &

Neurological disorders-Drug Targets 2014 Apr; 13(3):533-42.

16. Shahbaz S, Akhtar T, Iqbal Z. Optimization of nested RT-PCR for the detection

of a common fusion oncogene AML1/ETO of Acute Myeloid Leukemia in Pakistan.

Biologica 2014, 60 (2): 255-260. ISSN 2313 – 206X.

17. Karim S; Ansari SA; Rasool S; Iqbal Z; Sohrab SS; Abuzenadah AM and Al-

Qahtani M. Transcriptomics study of neurodegenerative disease: Emphasis on

synaptic dysfunction mechanism in Alzheimer’s disease. CNS Neurol Disord Drug

Targets. 2014;13(7):1202-12.

18. Alanazi A, Alsalmeh M, Alsomali O, Almurshdi AM, Alabdali A, Al-Sulami

M, Al-Nemer A, Al-Qusairy A, Aloraibi S and Iqbal Z. Poor Basic Life Support

Awareness among Medical and College of Applied Medical Sciences Students

Necessitates the Need for Improvement in Standards of BLS Training and Assessment

for Future Health Care Providers. Middle-East Journal of Scientific Research 21 (5):

Page 4 of 31

Page 5: CV Dr Iqbal 21.12.2015

848-854, 2014. DOI: 10.5829/idosi.mejsr.2014.21.05.82335

http://www.idosi.org/mejsr/mejsr21%285%2914/21.pdf

19. Alanazi A, Al Moamary M, Ismaeli T, Alanazi AN, Olayan LH, Alanazi AM,

Abu Nurah HY, Iqbal Z and Qureshi S. The Reliability of the Arabic Version of the

Asthma Knowledge Questionnaire and Assessment of the Level of Asthma Awareness

among Parents of Children with Asthma in Saudi Arabia. Middle-East Journal of

Scientific Research 20(4):412-418, 2014. DOI: 10.5829/idosi.mejsr.2014.20.04.82258.

http://www.idosi.org/mejsr/mejsr20%284%2914/2.pdf

20. Iqbal Z , Aleem A, Iqbal M,…, Khalid AM et al. Detection of pre-existing

BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic phase

chronic myeloid leukemia patients is associated with imatinib resistance: First large-

scale study with implication in post-Imatinib era. PLoS ONE 2013; 8(2): e55717.

doi:10.1371/journal.pone.0055717.

21. Aleem A, Anjum F, Algahtani F, Iqbal Z, Alsaleh K. Clofarabine in the

treatment of elderly patients with acute myeloid leukemia. Asian Pac J Cancer Prev.

2013; 14(2):1089-92.

22. Awan T, Iqbal Z, Aleem A, Sabir N, Absar M, Rasool M et al, . Five Most

Common Prognostically Important Fusion Oncogenes are Detected in the Majority of

Pakistani Pediatric Acute Lymphoblastic Leukemia Patients and are Strongly

Associated with Disease Biology and Treatment Outcome. Asian Pac J Cancer Prev.

2012; 13(11):5469-5475.

23. Iqbal Z . Molecular Hematology in Leukemia Biology and Treatment: Past,

present and future. J. App. Hematol. 2012 October; 3(2):55-61.Page 5 of 31

Page 6: CV Dr Iqbal 21.12.2015

24. Begum M, Karim S, Malik A, Khurshid R, Asif M, Salim A, Nagra SA, Zaheer

A, Iqbal Z, Abuzenadah AM, Alqahtani MH, Rasool M.CA 15-3 (Mucin-1) and

Physiological Characteristics of Breast Cancer from Lahore, Pakistan. Asian Pac J

Cancer Prev. 2012; 13(10):5257-61.

25. Aleem A, Al Diab AR, Alsaleh K, Algahtani F, Alsaeed E, Iqbal Z, El-Sherkawy

MS. Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients.

Asian Pac J Cancer Prev., 2012; 13(4):1311-5.

26. Sabir N, Iqbal Z , Aleem A, Awan T, Naeem T, Asad S, et al. Prognostically

Significant Fusion Oncogenes in Pakistani Patients with Adult Acute Lymphoblastic

Leukemia and Their Association with Disease Biology and Outcome. Asian Pac J

Cancer Prev., 2012;13(7):3349-55..

27. Iqbal Z , Manzoor F, Iqbal M, Ali S, Sheikh N, Khan M; Aleem A , Tanveer A.

Frequency of BCR-ABL Fusion Oncogene Splice Variants Associated with Chronic

Myeloid Leukemia (CML). Journal of Cancer Therapy, 2011, 2, 176-180.

28. Malik S, Hanif A, Khokher S, Iqbal Z, Rana S, Imran M, Bilal M, Arslan M.

Association of genetic and non-genetic risk factors with specific BRCA mutation

positive breast cancers in some Pakistani females. Pak J Physiol 2009;5(1): 51-57.

Page 6 of 31

Page 7: CV Dr Iqbal 21.12.2015

29. Iqbal Z., Iqbal M. and Akhtar T. Frequency of BCR-ABL fusion oncogene in

Pakistani childhood acute lymphoid leukaemia (ALL) patients reflects ethnic

differences in molecular genetics of ALL.J. Paed. Hemat. Oncol., 2007, 29 (8): 585.

30. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Ahmad M. Khalid. Case study of

primary Imatinib resistance and correlation of BCR-ABL multiple mutations in

chronic myeloid leukemia. Therapy (2004), 1(2): 249-254.

31. Iqbal Z., Siddiqui R.T. and Qureshi J. A. Two different point mutations in BCR-

ABL gene ATP-binding domain conferring primary Imatinib resistance in a chronic

myeloid leukemia (CML) patient: a case report. Biol. Proced. Online 2004; 6(1): 144-

148.

32. Zafar Iqbal , Ijaz Shah, Aamer Aleem, Mubashar Naqvi, Ammara Tahir, et al.

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly

diagnosed chronic phase CML patients and their association with imatinib resistance.

Nature Precedings Online. 28 November 2011.

http://precedings.nature.com/documents/6645/version/1.

33. Iqbal Z., Siddiqui R. T. and Qureshi J. A. Detection of point mutations

conferring acquired and natural Gleevec resistance in chronic myeloid leukemia

patients. J. Pak. Med. Assoc., December 2003, 53(12): 9-10.

Page 7 of 31

Page 8: CV Dr Iqbal 21.12.2015

34. Tanveer, A., and Iqbal, Z. 2000. Isolation of Bacillus sp., from water samples

collected from snail habitats and its evaluation as biomolluscicide. Punjab Univ. J.

Zool., 15: 171-181.

35. Iqbal Z., Muqaddas A. and Tanveer A. Evaluation of Bacillus sp. as

biomolluscicide against freshwater snail Lymnaea acuminata. Punj. Univ. J. Zool.,

2000, 9: 50-57.

36. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on bacteria isolated from

freshwater physid snail and their evaluation as snail controlling agent. Acta Scientia,

January 1999, 9: 58-68.

37. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on pathogenic bacteria

isolated from freshwater lymnaid snails and their evaluation as snail controlling agent.

Acta Scientia, January 1999, 9: 69-78.

Abstracts/research reports published in ISI-indexed journals:

38. Iqbal Z, Akram MA · Akhtar T, Khalid M, Zeba A· Aleem A, et al. High

Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib

Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic

Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine

Clinical Settings . Blood 12/2015; 126(23):5167. · 10.45 Impact Factor.

https://www.researchgate.net/profile/Zafar_Iqbal53/contributions

Page 8 of 31

Page 9: CV Dr Iqbal 21.12.2015

39. Aamer A, Al Wusibai F, AlSaleh K, Alqahtani F, Iqbal Z, Chaudhri NA, Al-

Momen AK. Multiple Brain Hemorrhages on Presentation in a Patient with

Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis

Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in

Leukemia Proliferation . Blood 12/2015; 126(23):5153. · 10.45 Impact Factor

40. Aljamaan K, Aljumah TK, Aloraibi S, Absar M, Iqbal Z. Low Representation of

ETV6-RUNX1 Fusion Oncogene in Pediatric Acute Lymphoblastic Leukemia Patients

from Saudi Arabia and Strong Association with Clinical Response to Day-14 of

Remission Induction Therapy . Blood 12/2015; 126(23):4987. · 10.45 Impact Factor

41. Zafar Iqbal, Tashfin Awan, Tanveer Akhtar, Aleem Aamer, Noreen Sabir,

Muhammad Absar, Iqbal Mudassar, Ahmad Mukhtar Khalid, Giuseppe Saglio,

Mahmood Rasool, and Akhtar Hussain. High Frequency Of BCR-ABL/t(22;9)

Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL

Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors

In Pediatric ALL Treatment Protocols. Blood 2013 122:3908.

42. Zafar Iqbal, Saba Shahzadi, Tanveer Akhtar, Aleem Aamer, Ahmad Mukhtar

Khalid, and Iqbal Mudassar. BCR-ABL Splice Variants In Three Phases Of CML:

Association With Disease Biology and Response To Imatinib. Blood 2013 122:5191.

43. Zafar Iqbal , Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad

Sultan, et al. Characterization of Common Fusion Oncogenes As Prognostic

Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need

Page 9 of 31

Page 10: CV Dr Iqbal 21.12.2015

for Genetic Testing At Presentation, Molecular Prognostication and Differential

Treatment. Blood (ASH Annual Meeting Abstracts) 120 (21): 5115. (Impact Factor

9.90)

44. Zafar Iqbal , Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad

Sultan, et al. Detection of Five Common Fusion Oncogenes in Pakistani Children with

Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and

Treatment Outcome. Blood (ASH Annual Meeting Abstracts) 120 (21): 5124. (Impact

Factor 9.90)

45. Zafar Iqbal , Tashfeen Awan, Mudassar Iqbal, Noreen Sabir. High frequency of

BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as

revealed by RT-PCR and interphase FISH: association with disease biology and

treatment outcome. J Clin Oncol 30, 2012 (suppl): 6612 (Proceedings of 2012 Annual

Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA). (Impact

Factor 18.372)

46. Zafar Iqbal , Mudassar Iqbal, Tanveer Akhtar, Mubashar Iqbal Naqvi, Ammara H

Tahir, Tariq Jameel Gill, et al . Presence of Prior-to-Treatment BCR-ABL Mutations

In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and

Their Correlation with Imatinib Resistance: Implications of Cancer

Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of

Page 10 of 31

Page 11: CV Dr Iqbal 21.12.2015

BCR-ABL+ Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (21): 2278.

(Impact Factor 9.90)

47. Z Iqbal , N Sabir, M Iqbal, A Tashfeen, A Aleem, A Mukhtar Khalid, T Akhtar.

Poor Outcome Of TCF3-PBX1 Despite Its Association With Favorable Risk Factors

Stresses The Need For Intensified Remission Therapy For Patients Of This Genetic

Subgroup In Adult Acute Lymphoid Leukemia. Haematologica 2013; 98(s1): 264.

EHA Abstract n. P625 (Impact Factor 6.424).

48. Z Iqbal , A Tashfeen, M Iqbal, N Sabir, A Aleem, A Mukhtar Khalid, T Akhtar.

High Frequency of BCR-ABL In Pediatric Acute Lymphoid leukemia with Poor

Outcome Identifies The Immediate Need For Incorporation of Imatinib And Other

Tyrosine Kinase Inhibitors In Treatment Protocols. Haematologica 2013; 98(s1): 268.

EHA Abstract n. P635 (Impact Factor 6.424).

49. Iqbal Z , Li-Juan Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer

A.. First comprehensive study on pre-existing BCR-ABL KD mutations and

subsequent Imatinib resistance in CML patients: Value of pre-treatment genetic testing

and implication in patient-tailored therapy of Leukaemia. Annals of Oncology, May

2008, 19 (3): 40-41.

50. Iqbal Z., Baig S.M., Aziz Z. and Akhtar T. Clinical significance of pre-existing

BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML)

patients: implication in prognosis and Imatinib follow-up studies. Annals of Oncology,

2007, 18(Supp. 4): iv4.

Page 11 of 31

Page 12: CV Dr Iqbal 21.12.2015

51. Iqbal Z. High frequency of pre-existing BCR-ABL gene ATP-binding domain

mutations associated with natural Gleevec resistance in chronic myeloid leukemia

(CML) patients. Haematologica, 2006; 91(s3): 3.

52. Iqbal Z. Frequency of chromosomal abnormalities and corresponding fusion

oncogenes in acute lymphoblastic leukemia (ALL) patients of Pakistan and its

implication in differential diagnosis and prognosis of leukemia. Haematologica, 2006;

91(s3):65.

53. Iqbal Z. Co-existence of fusion transcripts SIL-TAL1 and BCR-ABL in a

paediatric acute lymphoblastic leukaemia (ALL) patient. Haematologica, 2006;

91(s3):6.

54. Iqbal Z and Tanveer A. Detection of double fusion transcripts/ oncogenes (BCR-

ABL, SIL-TAL1) in childhood acute lymphoblastic leukaemia (ALL). Haematologica,

2006; 91(s3):68.

55. Iqbal Z and Tanveer A. A comprehensive analysis of pre-existing BCR-ABL

gene ATP-binding domain mutations associated with natural Gleevec resistance in

chronic myeloid leukemia (CML) patients. Haematologica, 2006; 91(s3):93.

56. Iqbal Z and Tanveer A. First report of co-existence of double fusion transcripts

(BCR-ABL and E2A-PBX1) in t-cell acute lymphoblastic leukaemia (ALL).

Haematologica, 2006; 91(s3):68.

57. Iqbal Z. Eradication of Imatinib-resistance-conferring, pre-existing BCR-ABL

ATP-binding domain mutant clones by sustained interferon therapy in CML patients.

Haematologica, 2006; 91(s3):97

Page 12 of 31

Page 13: CV Dr Iqbal 21.12.2015

58. Iqbal Z and Tanveer A. Incidence of different fusion oncogenes in acute

lymphoblastic leukemia (ALL) patients from Pakistan: possible implication in

differential diagnosis, prognosis, treatment and management of ALL. Haematologica,

2006; 91(s3):64.

59. Iqbal Z. Detection of ring chromosome 21 and Philadelphia chromosome (t

9:22) in a chronic phase CML patient and its response to interferon and Imatinib

treatments. Haematologica, 2006; 91(s3):99.

60. Iqbal Z and Baig SM. Optimization of simple PCR assay for detection of Globin

gene deletions in alpha-thalassemia patients. Haematologica, 2006; 91(s3): 136.

61. Iqbal Z. Detection of BCR-ABL ATP-binding domain mutations in Imatinib

resistance CML patient who relapsed after bone marrow transplant. Haematologica,

2006; 91(s3): 139.

62. Iqbal Z, Aziz Z and Tanveer A. Clinical and molecular biological studies on

susceptibility and resistance to Imatinib in Pakistani CML patients: first

comprehensive report from South-East Asia. Haematologica, 2006; 91(s3):98.

Iqbal Z and Tanveer A. High incidence of BCR-ABL fusion oncogene in Pakistani

childhood acute lymphoid leukaemia (ALL) patients reflects ethnic differences in

molecular genetics of ALL. Haematologica, 2006; 91(s3):65.

63. Iqbal Z, Abid Sohail Taj and Tanveer a. Studies on post bone marrow transplant

(post-BMT) Imatinib resistance in a chronic myeloid leukaemia (CML) patient.

Haematologica, 2006; 91(s3): 139.

Page 13 of 31

Page 14: CV Dr Iqbal 21.12.2015

64. Iqbal Z, Aziz Z, Shah IH and Tanveer A. Interferon therapy prior to Imatinib

can eradicate pre-existing BCR-ABL ATP-binding domain mutations conferring

natural Imatinib resistance in CML patients. Haematologica, 2006; 91(s3):96

65. Iqbal Z, Aziz Z, Shah IH, Khalid M and Tanveer A. First report of ring

chromosome 21 and Philadelphia chromosome (BCR-ABL fusion gene) in a 40 years

old CML patient resistant to Hydroxyurea: response to interferon and Imatinib.

Haematologica, 2006; 91(s3):97.

66. Iqbal Z. Case report of co-existence of double fusion transcripts (BCR-ABL,

E2A-PBX1) in T-cell acute lymphoblastic leukaemia (ALL). Haematologica, 2006;

91(s3):64.

67. Siddiqui R. T., Qureshi J. A. and Iqbal Z. Development of quantitative

competitive reverse transcriptase PCR (QC-RT-PCR) for detection of minimal

residual disease (MRD) and monitoring anti-leukaemic therapy response in

philadelphia chromosome positive leukemia. Haematologica 2004, 89 (suppl.n.6):94.

68. Iqbal Z., Aziz Z., Siddiqui R.T., Qureshi J. A. and Khalid A.M. first report of

multiple point mutations in BCR-ABL gene ATP-binding domain conferring primary

Imatinib resistance in chronic myeloid leukemia patient. Haematologica 2004, 89

(suppl.n.6):97.

Articles presented at prestigious international Conferences (published

as proceedings):

Page 14 of 31

Page 15: CV Dr Iqbal 21.12.2015

69. Zafar Iqbal; Akhtar Tanveer; Shahid Mahmood Baig; Zeba Aziz; Mudassar

Iqbal; et al. T315I and M351T are the most frequent prior-to-Imatinib BCR-ABL

kinase domain mutations in chronic phase CML patients and lead to natural Imatinib

resistance. In: Online Proceedings of Second AACR (American Association for

Cancer Research)-Dead Sea International Conference on Advances in Cancer

Research: From the Laboratory to the Clinic, March 7-10, 2010, King Hussein Bin

Talal Convention Center, Dead Sea, Jordan.

70. Zafar Iqbal, Akhtar Tanveer, Mudassar Iqbal, Muhammad Ferhan, Shahid M.

Baig, Mubashar Iqbal Naqvi, et al. First comprehensive report of strong interplay of

genetic and environmental factors as well as high degree of ethnic and geographical

variations in biology of Leukemia as manifested by frequencies of common fusion

oncogenes of prognostic significance associated with different Leukemic subtypes in

Pakistani population. In: Online Proceedings of AACR (American Association for

Cancer Research) 100TH Annual Meeting—April 18-22, 2009; Colorado, Denver.

71. Zafar Iqbal, Zhao LiJuan, Shahid Baig, Zeba Aziz, Mudassar Iqbal, Ahmad

Khalid, and Tanveer Akhtar. Significance of pretherapeutic genetic testing in patient-

tailored therapy of leukemia as manifested by correlation of pre-Imatinib BCR-ABL

ATP-binding domain mutations and natural Imatinib resistance in CML patients. In:

Online proceedings of AACR (American Association for Cancer Research)

Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008;

Monterey, CA.

Page 15 of 31

Page 16: CV Dr Iqbal 21.12.2015

72. Iqbal Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer A

Interferon prior to Imatinib therapy eradicates pre-existing BCR-ABL ATP-binding

domain mutations conferring natural Imatinib resistance and leads to more

sustained/durable molecular response in chronic myeloid leukaemia. In: Proceedings

of, 6th Internal Symposium on Targeted Anti-cancer Therapies (TAT) 2008,

Bethesda USA, p. 39.

73. Iqbal Z., Baig S.M., Aziz Z., Akhtar T. Clinical significance of pre-existing

BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML)

patients: implication in prognosis and Imatinib follow-up studies. In: Proceedings of

5th International Symposium on Targeted Anticancer Therapies (TAT Congress),

Amsterdam, March 8-10, 2007, p.59.

74. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Tanveer A and Zeba Aziz. Unraveling

pharmacogenomic basis of primary Imatinib resistance: first report of multiple point

mutations in BCR-ABL gene ATP-binding domain conferring primary Imatinib

resistance in a ph chromosome positive chronic myeloid leukemia (CML) patient. In:

Proceedings of International Conference on Tumor Progression and Therapeutic

resistance, Philadelphia USA, November 8-9, 2004, pp: 56-5.

A. Articles submitted to ISI- indexed journals / Prestigious Conferences:

Page 16 of 31

Page 17: CV Dr Iqbal 21.12.2015

75. Tashfin A, Iqbal Z., Sabir N, et al. Immunophenotypic characterization of

Pakistani pediatric Acute Lymphoid Leukemia Patients with respect to molecular

subtypes, clinical parameters and treatment outcome. Asian Pac J Cancer Prev.

76. Sabir N, Iqbal Z., Tashfin A, et al. Studies on Immunophenotypic characteristics

of Pakistani adult Acute Lymphoid Leukemia Patients: Association with molecular

subtypes, clinical parameters and treatment outcome. Asian Pac J Cancer Prev.

77. Mahmood Rasool, Zafar Iqbal, Mohammed Hussain Alqahtani, Ishfaq Ahmed

Sheikh et al. Comparative study of alterations in Tri-iodothyronine (T3), Thyroxine

(T4) hormone levels in breast and ovarian cancer in local population. Intl J Oncol.

78. Mahmood Rasool, Zafar Iqbal, Ishfaq Ahmed Sheikh et al. Evaluation of

biochemical markers and malondialdehyde status in patients with thyroid gland

dysfunction receiving interferon therapy. Oncol Reports.

B. GENEBANK (Nucleotide / NCBI) submissions / Citations :

DNA sequences of Hepatitis B Virus (HBV) surface antigen gene (HBsAg) were submitted to

GeneBank (NCBI Core Nucleotide) in 2001-2002. This was a part of M.Phil. research. GeneBank

database sequences’ IDs are:

AY168835-45 (11 sequences)

AF388661-8 (08 sequences)

Clinical / Molecular Diagnostic (MDx) Experience:

Page 17 of 31

Page 18: CV Dr Iqbal 21.12.2015

1) Founder of Molecular Genetic Pathology Unit and pioneer in introducing molecular

diagnosis of hematological cancers and solid tumors at King Khalid University Hospital,

King Saud University College of Medicine, Riyadh, KSA.

(07-06-2010 to 14-05-2012).

2) Established Cancer Genetics Research & Molecular Diagnostics of Leukemia at

Department of Biotechnology, University of Sargodha, Pakistan (Jun-Nov, 2012).

3) Founder Scientist of Molecular Genetic Testing of Leukemia/Lymphoma and Solid

Tumors at Health Sciences Laboratories, Department of Zoology, University of the

Punjab, Lahore, Pakistan which is currently Pakistan’s largest centre for research,

teaching and molecular diagnostics in Molecular Hematology/Oncology.

(02-2006 to 12-2006 & 1-2009 to 23-12-2012)

4) Pioneer in introducing the molecular hematology/oncology tests and quality control

measures of infectious molecular diagnostics at Ammar Medical Complex, Chughtai

Lahore Laboratories Pakistan.

(12-2009 to 5-2010).

5) Introduced BCR-ABL molecular testing for diagnosis of Chronic Myeloid Leukemia

at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.

(04-2009 to 11-2009).

6) Introduced BCR-ABL mutation testing for Chronic Myeloid Leukemia drug-

resistance monitoring and co-established 8-color flow cytometry for diagnosis of

hematological malignancies at Shanghai Institute of Hematology of Rui-Jin Hospital,

Shanghai Jiao-Tong University School of Medicine China (2007-2008).

7) Developed Molecular Testing of Alpha Thalassemia, BRCA1/2 mutation testing in

Breast/ Ovarian cancers, Acute Leukemia and Familial Hypercholesterolemia

Molecular Testing (LDLR gene) for PIBS Diagnostics at Human Molecular Genetics

Page 18 of 31

Page 19: CV Dr Iqbal 21.12.2015

Laboratory, National Institute for Biotechnology and Genetic Engineering (NIBGE),

Faisalabad, Pakistan.

(5-2002 to 1-2006).

8) Introduced Molecular Testing of Acute Leukemia at Department of Pathology and

Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh,

Saudi Arabia.

(12-2006 to 3-2007).

Employment Record:

Assistant Professor (Medical Genetics / Molecular Hematology & Oncology) ,

CAMS, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz

Medical City, NGHA, Riyadh, Saudi Arabia (Since November 2012).

Quality Assurance and Academic Accreditation Program Officer (CLSP), CAMS,

King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (Since

February 2014).

Visiting Professor, “Hematology Oncology and Pharmacogenetic Engg. Sciences

(H.O.P.E.S.) Group, Department of Biotechnology, University of Sargodha, Sargodha,

Pakistan (06/2012 to 23-12-2012).

Visiting Scientist and Principal Investigator, “Hematology Oncology and

Pharmacogenetic Engg. Sciences (H.O.P.E.S.)” Program, Health Sciences/Parasitology

Research Group, Dep’t of Zoology, University of the Punjab, Lahore, Pakistan (1/2009 to

23-12-2012).

Assistant Professor and Group Leader Functional Molecular Cell Biology / Clinical

Hematology & Oncology: Centre for Research in Molecular Medicine (CRiMM) /

Page 19 of 31

Page 20: CV Dr Iqbal 21.12.2015

Institute of Molecular Biology and Biotechnology (IMBB), the University of Lahore,

Lahore, Pakistan (12/ 2009 to 05-06-2012).

Consultant Molecular Diagnostics / Genetics and In-charge PCR Laboratory,

Ammar Medical Complex and Chughtais Lahore Laboratories (CLL), Lahore. Pakistan

(12-2009 to 05-2010).

Jr. Research Scientist and Group Leader Hemato-oncology: Shaukat Khanum

Memorial Cancer Hospital and Research Centre, Lahore, Pakistan (5/2009 to 11/2009).

Senior Research Officer (SRO): Centre for Excellence in Molecular Biology (CEMB),

University of the Punjab Lahore Pakistan (1/2009 to 5/2009).

Post-doctoral Scientist (Functional Medical Genomics / Hematology and Oncology):

State Key Laboratory of Functional Medical Genomics, Shanghai Institute of

Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, China

(7/2007-12/2008).

Post-doctoral Researcher: “Hematology, Oncology and Pharmacogenetics” at

University of the Punjab, Lahore 54590, Pakistan (3/2007 to 7/2007).

Molecular Hematologist: King Faisal Specialist Hospital and Research Hospital

(KFSH&RC) Riyadh Saudi Arabia (12/2006 to 3/2007).

Researcher: “Hematology, Oncology and Pharmacogenetic-Engineering Sciences

(H.O.P.E.S.), Health Sciences/Parasitology Research Group, Department of Zoology,

University of the Punjab, Lahore 54590, Pakistan” (2/2006 to 11/2006).

Research Officer: Department of Physiology and Cell Biology, University of Health

Sciences, Lahore 54600, Pakistan (4/2006 to 9/2006).

Page 20 of 31

Page 21: CV Dr Iqbal 21.12.2015

Scientific Officer / Junior Scientist: Cancer Genetic/Human Molecular Genetics

Laboratory, at National Institute for Biotechnology & Genetic Engineering (NIBGE),

Faisalabad, Pakistan from (5/2002 to 1/2006).

Research officer: H.O.P.E.S., Dep’t. of Zoology, University of the Punjab, Lahore,

Pakistan (3/2001 to 5/2002).

Research Scholar (Molecular Biomedical sciences): Center of Excellence in Molecular

Biology (CEMB), Punjab University Lahore Pakistan (3/1999-2001). At the completion

of research at CEMB, Degree of Master of Philosophy (MPhil) in Molecular Biology was

awarded.

Molecular/Genetic Techniques Hands-on Training:

DNA/RNA/Protein extraction using Robotic arms (MagNApure, Roche), Kits and

Manual methods (TriZol and Phenol-Chloroform Extraction methods).

Real Time Q-PCR: Application in Gene Expression Profiling, Anti-cancer therapy

selection & follow-up, Genetic studies (Mutation detection, SNPs etc.).

M.R.D. (minimal residual disease) monitoring in Leukemia using RTQ-PCR.

Multiplex RT-PCR & ARMS-PCR (mutation/SNP detection) for Cancer genetic testing.

DNA sequencing using ABI310 and ABI 3500 Genetic Analyzers.

Cancer F.I.S.H. (Fluorescent in situ Hybridization) using CytoVision 7.2 system.

Cancer Microarray (cytoband) analysis using Affymetrix microarray system.

Sequenom (DNA Mass Spectrometry) for Cancer Gene mutations and SNP typing.

Intensive use of bioinformatics, biostatistics and Databases for DNA/RNA/Protein

analysis e.g. designing primers/probes, DNA sequencing, experimental design etc.

Recombinant DNA Techniques: Cloning, transformation, Restriction Analysis, etc.

Page 21 of 31

Page 22: CV Dr Iqbal 21.12.2015

Confocal Microscopy, Fluorescent Microscopy and bright- field microscopy.

Flow Cytometry, Fluorescent assisted cell sorting and Immunocytochemistry.

Western blotting.

Cell culturing (Human, Mice, bacteria); viral culturing; Chromosomal analysis etc.

Lentiviral/Liposomal gene transfer to mouse and Human tissues; mice experiments.

Eleven year experience of molecular diagnostics (MDx) as well as writing, planning,

execution, reporting, publishing and laboratory management of research / diagnostic /

clinical investigation projects in R&D sector and Hospitals as well as teaching/co-

supervising BS/MS/Phil students as well as PhD and post-PhD fellows at University level.

Research Funding:

1. “Studies on frequencies and disease progression potential of candidate

Lymphoid and Myeloid lineage gene mutations in Chronic Myeloid Leukemia

Lymphoid and Myeloid blast Crisis CD34+ stem cells” by KACST (Project # 14-

MED487-22), SR. 2 million (Co-investigator).

2. “Highthoughput cytogenetic and molecular analysis to reveal novel

abnormalities associated with transformation to advanced disease and tyrosine

kinase inhibitor resistance in Chronic Myeloid Leukemia” , by King Abdulaziz

City for Science and Technology (Project # ARP-35-200, funded amount Saudi Riyal

2 million), at National Guard Health Affairs, Riyadh, Saudi Arabia (Principal

Investigator).

Page 22 of 31

Page 23: CV Dr Iqbal 21.12.2015

3. “Studies on frequencies and disease progression potential of candidate

Lymphoid and Myeloid lineage gene mutations in Chronic Myeloid Leukemia

Lymphoid and Myeloid blast Crisis CD34+ stem cells” by King Abdulaziz City for

Science and Technology (Project # ARP-35-200, funded amount Saudi Riyal 2

million equivalent to Pk Rs. 54 million, 2015-2017), at National Guard Health

Affairs, Riyadh, Saudi Arabia (Co- Investigator).

4. “BCR-ABL mutations associated with resistance to imatinib in Chronic Myeloid

Leukemia patients”, by Higher Education Commission Pakistan (Project #

20-1370/R&D/09, funding amount PKRs 4.2 million, 2011-13), at Punjab University

Lahore Pakistan (Co-Investigator).

5. “Molecular genetic studies of Leukemia: Implication in differential diagnosis,

prognosis and anti-leukemia therapy monitoring”, by Shaukat Khanum Memorial

Cancer Hospital & Research Centre (SKMCH&RC) Lahore Pakistan (Funded amount

PKRs 3.0 million, 2009), at SKMCH&RC, Lahore, Pakistan (Principal Investigator).

6. Post-doctoral Fellowship Project “Functional characterization of NUP98-IQCG

fusion oncogene in acute leukemia”, funded by Shanghai Education Commission

Shanghai China (2007-2008), at Shanghai Institute of Hematology, Shanghai Jiao-

Tong University School of Medicine, Shanghai, China (Postdoctoral Scientist).

7. “Y-chromosome microdeletions associated with male infertility in Pakistan”, funded

by Pakistan Science Foundation (Funded amount 1.0 million, 2004-6), at National

Page 23 of 31

Page 24: CV Dr Iqbal 21.12.2015

Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan

(Co-Investigator).

8. Project “Low density lipoprotein receptor gene (LDLR) mutations associated with

familial hypercholesterolemia”, funded by Pakistan Science Foundation (Funded

amount 1.0 million, 2006-8), at NIBGE, Faisalabad, Pakistan (Co-investigator).

MS/MPhil and PhD Research Co-supervision:

Completed / Thesis defense:

PhD supervised at University of the Punjab Lahore, 2010-2015.

1. PCR-based analysis of prognostically important fusion oncogenes in Pakistani

pediatric acute lymphoblastic leukemia patients and their association with disease

biology and treatment outcome (Tashfeen Awan, Hematology/ Genetics) 2013.

2. PCR-based analysis of prognostically important fusion oncogenes in Pakistani

pediatric acute lymphoblastic leukemia patients and their association with disease

biology and treatment outcome (Noreen Sabir, Hematology/ Genetics) 2014.

3. BCR-ABL mutations associated with Imatinib resistance and advanced disease phases

in Chronic Myeloid Leukemia (Afia M. Akram, Hematology /Genetics) 2014.

4. Molecular Genetic studies of Acute Myeloid Leukemia in Pakistan (Sana Shahbaz,

Hematology/Genetics) 2015; Thesis submitted 2015.

Page 24 of 31

Page 25: CV Dr Iqbal 21.12.2015

MS/MPhil (University of The Punjab, Lahore) (Cancer Pharmaco-genomics) 4

MPhil (University of Health Sciences, Lahore) (Cancer Genetics) 1

MPhil (NIBGE Faisalabad) MS/MPhil (Human Molecular Genetics) 2

In Process (University of the Punjab Lahore Pakistan):

One Post-doctoral Fellow (Molecular Basis of Drug Resistance in Leukemia).

7 PhDs (Molecular Genetics of Hematological Neoplasms and Breast Cancer).

One MS/MPhil (Genetics of Nilotinib resistance in Ph+ Leukemia).

Research Awards:

1. Wallace H. Coulter Foundation-ASH (American Society of Hematology) Abstract

Achievement Award, ASH Annual Meeting, Dec. 2014, San Francisco, CA, USA.

2. ASH Abstract Achievement Award, ASH Annual Meeting, Dec. 2013, New Orleans, LA.

3. European Hematology Association Travel Grant 2013: Annual Meeting, Sweden.

4. ASH (American Society of Hematology) Travel Award, ASH Annual Meeting, Dec. 2010.

5. Susan G. Komen / AACR Scholar-in-Training Award 2010: American Association for

Cancer Research (AACR) Award, AACR Special Conference “Advances in Cancer Research-

From Laboratory to Clinic” at Amman, Jordan, from March 07-10, 2010.

6. AACR / ITO EN Scholar-in-Training Award 2009: AACR 100TH Annual Meeting—April

18-22, 2009; Colorado, Denver.

7. Shanghai Education Commission Fellowship (Clinical Hematology): Research/clinical

training at Shanghai Jiao-Tong University College of Medicine China in the field of Functional

Medical Genomics / Clinical Hematology.

Page 25 of 31

Page 26: CV Dr Iqbal 21.12.2015

8. SIES Award 2006: Italian Society of Experimental Hematology (SIES) in IX Congress of this

society (September 2006); research paper “Role of Pre-existing BCR-ABL gene ATP-binding

domain mutations in outcome of Gleevec therapy in CML”.

9.PSF Travel Award: Pakistan Science Foundation (PSF) Travel award to participate in VIII

Congress of Italian Society of Experimental Hematology (September 2006).

10. Best Cancer Researcher Award: Awarded by Society of Clinical Oncology Pakistani

(SCOP) on occasion of their 10th National and 1st International cancer conference (18th-21st

December 2003), for best cancer research article in the field of Leukemia.

11. Educational Scholarships : Educational Merit Scholarships by University &

Educational Boards in Ph.D., M.Phil., Grade-12, Grade-10 and Grade-5 classes (1985-2002).

University / Medical College Teaching and Academic Experience:

1. Curriculum design and teaching a course on “Molecular Pathology Course for Pathology

Residents / Fellows / Consultants ” at Department of Pathology, Kind Abdulaziz Medical

City, National Guard Health Affairs, Riyadh, Saudi Arabia (2013-2014).

2. Curriculum design and Teaching subjects of “Medical Genetics, Molecular Diagnostics

and Immunology” at College of Applied Medical Sciences and College of Medicine, KSA-

UHS, National Guard Health Affairs, Riyadh, Saudi Arabia (Since November 2012).

3. Taught the subjects of “Molecular Genetics and Hematology/Oncology” to “Medical

Residents and Fellows of KSU-Fellowship Program in Hematology / Pathology” at

Department of Pathology, King Saud University College of Medicine, King Khalid

University Hospital, Riyadh (Since 07-06-2010).

4. Developed the CURRICULA for MS/PhD program in Molecular Genetic Pathology at King

Saud University College of Medicine, Riyadh, Saudi Arabia.

Page 26 of 31

Page 27: CV Dr Iqbal 21.12.2015

5. Developed the 5-year program for research, teaching and clinical services at Molecular

Genetic Pathology Unit, King Saud University College of Medicine, King Khalid University

Hospital, Riyadh, Saudi Arabia.

6. Taught the subjects of “Advanced Molecular Biology, Cancer Biology, Molecular

Hematology, Leukemia Genetics, Molecular Pathology and Advanced Experimental

Biology” to “BS, MS and PhD students” , as Assistant Professor at Centre for Research in

Molecular Medicine (CRiMM), Institute of Molecular Biology and Biotechnology (IMBB),

The University of Lahore, Lahore, Pakistan.

7. Developed the curricula for above-mentioned subjects (12-2009 to 06-2010).

8. A: Taught the subjects of “Advanced Molecular Biology, Human Cytogenetics,

Leukemia Genetics, Cancer Biology, Molecular Hematology and Molecular Pathology”

to “MS and PhD students” as Visiting Scientist at Faculty of Biological Sciences, Dep’t of

Zoology, University of the Punjab, Lahore, Pakistan. B: Developed the

curricula for the mentioned subjects (1-2009 to 06-2010).

9. Taught the subjects of “Human Molecular Genetics, Molecular Hematology and Cancer

Genetics” to “MS /PhD students” as Scientific Officer at Human Molecular Genetics

Group , Health Biotechnology Division, National Institute for Biotechnology & Genetic

Engineering (NIBGE), Faisalabad, Pakistan from (5/2002 to 1/2006).

10. Taught the subjects of “Molecular Parasitology and Vector Biology” to “BS and MS

students” as Research Officer at Faculty of Biological Sciences, Dep’t of Zoology,

University of the Punjab, Lahore, Pakistan (3-2001 to 05-2002).

Membership of International Research Bodies/Agencies:

Page 27 of 31

Page 28: CV Dr Iqbal 21.12.2015

I. American Association for Cancer Research (AACR) 2008-2011

II. European Hematology Association (EHA) 2012-2014

III. American Society of Clinical Oncology (ASCO) 2012

IV. American Society for Pediatric Hematology and Oncology (ASPHO) 2007-2010

V. Saudi Society for Bone Marrow Transplantation (SSBMT) 2012-continued

VI. National Academy of Young Scientists (NAYU), Pakistan. 2012-continued

VII. Fellow, Shanghai Institute of Hematology (SIH), China. 2007-2008

VIII. President Pakistan Society for Molecular and Clinical Hematology (A.S.H. Partner)

Congress and Symposia Attended:

1. American Society of Hematology (ASH) Annual Meeting, Dec. 2014, San Francisco, CA.

2. European Hematology Association (EHA), Annual Meeting June 2014 Milan Italy.

3. ASH-Highlights Asia Meeting, 29-30th Mar 2014, Singapore.

4. ASH Annual Meeting, Dec. 2013, New Orleans, LA.

5. Second Saudi CML Summit 2011. Hilton Hotel Jeddah, Saudi Arabia (Jan 27, 2011).

6. Saudi Hematology Association Conference, Riyadh Saudi Arabia (Sep 29, 2010).

7. American Association for Cancer Research (AACR) Special Conference “Advances in

Cancer Research-From Laboratory to Clinic” at Amman, Jordan, (March 07-10, 2010).

8. 12th National Haematology Conference, Lahore, Pakistan (Feb 9-16, 2010).

9. AACR 100th Annual Meeting, Denver, .Colorado. (April 18-22, 2009)

10. 21st Century Challenges in Hematology” (20th Anniversary of Shanghai Institute of

Hematology, Rui-Jin Hospital), Jiao-Tong University School of Medicine, China (Oct 2008).

Page 28 of 31

Page 29: CV Dr Iqbal 21.12.2015

11. 5th International Symposium on Targeted Anticancer Therapies (TAT Congress),

Amsterdam, Netherlands (March 8-10, 2007).

12. IX Congress, Italian Society of Experimental Hematology, Milano, Italy (September 2006).

13. International Conference on Tumor Progression and Therapeutic resistance, Philadelphia

USA (November 8-9, 2004).

14. 10th National/1st International cancer conference, Pakistani Society of Clinical Oncology,

Pearl continental Hotel, Peshawar, Pakistan (18th-21st December 2003).

15. Symposium on "Molecular Biology Approach to Diagnostics & Prevention of Genetic

Diseases, CEMB, Punjab University, Lahore, Pakistan (Feb.4, 2000).

16. 17th Pakistan Congress of Zoology University of the Sind, Karachi, Pakistan (4/1997).

17. 18th Pakistan Congress of Zoology University of the Punjab, Lahore, Pakistan (4/1998).

References:

1) Dr Rizwan C. Naeem, MD, PhD, FACMG, DABMG

Professor of Pathology & Director Molecular Pathology

Director ABMG Lab Genetics Fellowship Program

Albert Einstein College of Medicine and Montefiore Medical Centre

Bronx, NY, USA.

Phone: 718-405-8101; Fax: 718-931-3637

Email: [email protected]

Page 29 of 31

Page 30: CV Dr Iqbal 21.12.2015

2) Professor Dr Masood A. Shammas, PhD

Director, Translational Genomic Instability Program

Jeromy Lipper Myeloma Center, Harvard (Dana Farber) Cancer Institute

Research Health Scientist, VA Boston Health Care System

Harvard Medical School at VAMC

Harvard University, West Roxbury, MA 02132

Phone: 1-857-203-6172 Office. Fax: 1-781-507-1075 Cell

E-mail: [email protected]

3) Professor Walid E. Khalbuss, MD PhD

Dept. of Pathology, University of Pittsburgh, Pittsburgh, PA, USA

5230 Centre Ave, Pittsburgh, PA 15232.

Director, GE Healthcare at National Guard Health Affairs, Riyadh, Saudi Arabia.

Phone: (412) 623-1109, Fax: (412) 682-6450

E-mail: [email protected] ; [email protected]

4) Dr Muhammad Faiyaz-Ul-Haque, MPhil PhD FRCPath

Professor, Consultant & Director, Molecular Pathology Unit

Department of Pathology and Laboratory Medicine

College of Medicine and King Khalid University HospitalPage 30 of 31

Page 31: CV Dr Iqbal 21.12.2015

King Saud University, Riyadh 11461, Pakistan.

Phone: +966-1-469-9377

E-mail: [email protected] , [email protected]

5) Dr Muhammad Azhar Chishti, PhD

Scientist, University of Toronto

4424 Marshdale Court, Mississauga ONT L5M 4G1, Canada.

Phone: +1-905-593-8835

E-mail: [email protected]

6) Professor Tanveer Akhtar, PhD Post-doctorate (Manitoba)

Director, Higher Education Project in Hematology, Oncology and

Pharmacogenetic Engineering Sciences (HOPES), Health Sciences Laboratories,

Faculty of Biological Sciences, Department of Zoology, University of the Punjab,

Lahore 54590, Pakistan.

Phone: +92-321-4257861, +92-42-9923124

E-mail: [email protected]

7) Professor Ahmad M Khalid, PhD

Director, Department of Biotechnology

University of Sargodha, Pakistan.

Phone: +92-300-8651900

E-mail: [email protected]

Page 31 of 31